NOTE: This order is nonprecedential. United States Court of Appeals
for the Federal Circuit
AMARIN PHARMA, INC., AMARIN
PHARMACEUTICALS IRELAND LIMITED,
MOCHIDA PHARMACEUTICAL CO., LTD.,
Plaintiffs-Appellants
v.
HIKMA PHARMACEUTICALS USA INC., HIKMA
PHARMACEUTICALS PLC,
Defendants-Appellees HEALTH NET LLC,
Defendant
2023-1169
Appeal from the United States District Court for the District of Delaware in No. 1:20-cv-01630-RGA-JLH, Judge Richard G. Andrews.
SUA SPONTE
Before MOORE, Chief Judge, MAYER and LOURIE, Circuit
Judges
22 AMARIN PHARMA, INC. v. HIKMA PHARMACEUTICALS USA INC.
O R D E R
Upon consideration of the judgment of the Supreme Court of the United States in Hikma Pharmaceuticals USA Inc., et al. v. Amarin Pharma, Inc., et al., No. 24-889, IT IS ORDERED THAT:
The mandate of this court that issued October 24, 2024, is recalled, the appeal is reinstated, and this court’s June 25, 2024, opinion and judgment are vacated. We further remand this case to the United States District Court for the District of Delaware for further proceedings consistent with the Supreme Court’s decision.
FOR THE COURT
July 15, 2026 Date